Back to listing

Resources

Whitepaper

The Clinical Impact of Floaters

Whether patients with symptomatic floaters should be offered treatment or told to “carry on regardless” continues to be debated. Read the whitepaper to learn more.

This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More

QUANTEL MEDICAL COMPLETES ACQUISITION OF ELLEX

Quantel Medical has completed its acquisition of Ellex, including the company’s laser and ultrasound technology solutions (with the exception of 2RT® and iTrack®), via the financial holding company Lumibird Medical.

The coming together of these two companies—both renowned in the field of ophthalmology—represents a real milestone in their history. Quantel Medical and Ellex have a shared heritage in the development of cutting-edge technologies for the diagnosis and treatment of the leading causes of blindness worldwide: glaucoma, cataracts, AMD and diabetic retinopathy.